Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HJ-004-02 in EGFR-mutated Non-squamous NSCLC
NCT07361237Phase 1Recruiting
- Sponsor
- Tongji University
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HJ-004-02 in non-small cell lung cancer (NSCLC), sponsored by Tongji University. Primary endpoints: Adverse Events at 1 year and Dose-Limiting Toxicity at 4 weeks. Started Dec 2025; status: recruiting.
02
Drugs
HJ-004-02
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07361237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07361237.